BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10919598)

  • 1. Fas ligand-deficient gld mice are more susceptible to graft-versus-host-disease.
    van den Brink MR; Moore E; Horndasch KJ; Crawford JM; Murphy GF; Burakoff SJ
    Transplantation; 2000 Jul; 70(1):184-91. PubMed ID: 10919598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fas-deficient lpr mice are more susceptible to graft-versus-host disease.
    van Den Brink MR; Moore E; Horndasch KJ; Crawford JM; Hoffman J; Murphy GF; Burakoff SJ
    J Immunol; 2000 Jan; 164(1):469-80. PubMed ID: 10605044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
    Marks L; Altman NH; Podack ER; Levy RB
    Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis.
    Jiang Z; Podack E; Levy RB
    Blood; 2001 Jul; 98(2):390-7. PubMed ID: 11435308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
    Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
    Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
    Tsukada N; Kobata T; Aizawa Y; Yagita H; Okumura K
    Blood; 1999 Apr; 93(8):2738-47. PubMed ID: 10194454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function.
    Baker MB; Riley RL; Podack ER; Levy RB
    Proc Natl Acad Sci U S A; 1997 Feb; 94(4):1366-71. PubMed ID: 9037059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
    Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
    Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteopontin attenuates acute gastrointestinal graft-versus-host disease by preventing apoptosis of intestinal epithelial cells.
    Kawakami K; Minami N; Matsuura M; Iida T; Toyonaga T; Nagaishi K; Arimura Y; Fujimiya M; Uede T; Nakase H
    Biochem Biophys Res Commun; 2017 Apr; 485(2):468-475. PubMed ID: 28192120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A major role for the Fas pathway in acute graft-versus-host disease.
    Via CS; Nguyen P; Shustov A; Drappa J; Elkon KB
    J Immunol; 1996 Dec; 157(12):5387-93. PubMed ID: 8955186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation.
    Hattori K; Hirano T; Oshimi K; Yagita H; Okumura K
    Leuk Lymphoma; 2000 Aug; 38(5-6):553-61. PubMed ID: 10953977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
    J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
    Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
    J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease.
    Maeda Y; Levy RB; Reddy P; Liu C; Clouthier SG; Teshima T; Ferrara JL
    Blood; 2005 Mar; 105(5):2023-7. PubMed ID: 15466930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen-primed CD8+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing.
    Komatsu M; Mammolenti M; Jones M; Jurecic R; Sayers TJ; Levy RB
    Blood; 2003 May; 101(10):3991-9. PubMed ID: 12521999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft-versus-host-disease-associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway.
    Iwasaki T; Hamano T; Saheki K; Kuroiwa T; Kataoka Y; Takemoto Y; Ogata A; Fujimoto J; Kakishita E
    Immunology; 2000 Jan; 99(1):94-100. PubMed ID: 10651946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice.
    Baker MB; Altman NH; Podack ER; Levy RB
    J Exp Med; 1996 Jun; 183(6):2645-56. PubMed ID: 8676085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.